-
Tytuł:
-
Edema Associated With Everolimus de Novo.
-
Autorzy:
-
Gago LG; Nephrology Department, A Coruña University Hospital, A Coruña, Spain.
Jarrín DA; Nephrology Department, A Coruña University Hospital, A Coruña, Spain.
Magariños CR; Nephrology Department, A Coruña University Hospital, A Coruña, Spain.
Rodríguez MC; Nephrology Department, A Coruña University Hospital, A Coruña, Spain.
Hermida TF; Nephrology Department, A Coruña University Hospital, A Coruña, Spain.
Muñiz AL; Nephrology Department, A Coruña University Hospital, A Coruña, Spain.
Rivera CF; Nephrology Department, A Coruña University Hospital, A Coruña, Spain. Electronic address: .
Hernández ÁA; Nephrology Department, A Coruña University Hospital, A Coruña, Spain.
-
Źródło:
-
Transplantation proceedings [Transplant Proc] 2021 Nov; Vol. 53 (9), pp. 2681-2684. Date of Electronic Publication: 2021 Oct 05.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Publication: New York, N.Y. : Elsevier Science Inc.
Original Publication: New York Stratton.
-
MeSH Terms:
-
Everolimus*/adverse effects
Immunosuppressive Agents*/adverse effects
Edema/chemically induced ; Graft Rejection ; Graft Survival ; Humans ; Mycophenolic Acid/adverse effects ; Tacrolimus
-
Substance Nomenclature:
-
0 (Immunosuppressive Agents)
9HW64Q8G6G (Everolimus)
HU9DX48N0T (Mycophenolic Acid)
WM0HAQ4WNM (Tacrolimus)
-
Entry Date(s):
-
Date Created: 20211008 Date Completed: 20211130 Latest Revision: 20211130
-
Update Code:
-
20240104
-
DOI:
-
10.1016/j.transproceed.2021.07.053
-
PMID:
-
34620498
-
Background: The appearance of edema limits the use of everolimus de novo together with tacrolimus and steroids in kidney transplantation. We aimed to investigate the frequency and characteristics of patients with edema and compare them according to the type of immunosuppression.
Methods: We studied 150 kidney transplant recipients between 2015 and 2017 based on receiving everolimus de novo (group A) or mycophenolic acid derivatives (group B).
Results: We analyzed 50 patients in group A and 100 in group B. Follow-up was 26.2 ± 10 months. Fifty-six patients presented edema (37.3%): 54% in group A and 29% in group B (P = .003). Edema was mild in 74% of patients in group A and 57.1% in group B. The probability of edema was 10.1%, 22.4%, and 41% at 3, 6, and 12 months, respectively, in group A vs 10.1%, 20.3%, and 25.4% in group B (P = .006). Patients were treated mostly with diuretics (14.3% in group A vs 27.6% in group B) and discontinuation of calcium channel blockers (46.4% in group A vs 48.3% in group B). Improvement was 70.4% in group A vs 60.7% in group B; patient worsening was 0% in group A vs 10.7% in group B; and there was no change in 29.6% in group A vs 28.6% in group B. We did not find differences in patient or graft survival in those who presented edema, regardless of the treatment group.
Conclusion: The use of everolimus and standard doses of tacrolimus caused edema in 54% of patients, with no impact on renal function or survival compared with mycophenolic acid derivatives. The edema was mostly of low intensity and improved in most patients.
(Copyright © 2021 Elsevier Inc. All rights reserved.)
